Lilly hungry enough for less-mega deals

Eli Lilly chief John Lechleiter may not be up for a mega-merger, but he is looking for acquisitions of as much as $15 billion now that Lilly has digested ImClone Systems. "I got hungry again about three weeks after ImClone got closed" in late November, Dr. Lechleiter told the Wall Street Journal. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.